Literature DB >> 17376013

An update on the pharmacological treatment of obsessive-compulsive disorder.

Leonardo F Fontenelle1, Antonio L Nascimento, Mauro V Mendlowicz, Roseli G Shavitt, Marcio Versiani.   

Abstract

The purpose of this article is to introduce the reader to an updated evidence-based drug treatment algorithm to be employed in patients with obsessive-compulsive disorder (OCD). Relevant studies were identified through a comprehensive review and classified according to the type of patients enrolled, the quality of the study design and the invasiveness, availability and complexity of the therapeutic approach. When ineffective, therapeutic trials with first-line strategies (such as the selective serotonin re-uptake inhibitors [SSRIs] and venlafaxine) should be followed by treatment approaches such as clomipramine, augmentation with antipsychotics or pindolol, SSRI megadoses or cognitive behavioral therapy. These therapeutic strategies are expected to help most patients with OCD. Additional approaches include intravenous clomipramine, oral morphine, 'heroic drug strategies', deep brain stimulation and functional neurosurgery. Independent studies are urgently needed to help identify the most promising drug treatment sequences for OCD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376013     DOI: 10.1517/14656566.8.5.563

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  9 in total

Review 1.  Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments.

Authors:  Leonardo F Fontenelle; Sanne Oostermeijer; Ben J Harrison; Christos Pantelis; Murat Yücel
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

2.  Attenuation of compulsive-like behavior by fluvoxamine in a non-induced mouse model of obsessive-compulsive disorder.

Authors:  Swarup Mitra; Abel Bult-Ito
Journal:  Behav Pharmacol       Date:  2018-06       Impact factor: 2.293

3.  Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive-Compulsive Disorder in Childhood.

Authors:  Ulku Akyol Ardic; Eyup Sabri Ercan; Ayse Kutlu; Deniz Yuce; Melis Ipci; Sevim Berrin Inci
Journal:  Child Psychiatry Hum Dev       Date:  2017-10

4.  Specificity of fear and disgust experienced during traumatic interpersonal victimization in predicting posttraumatic stress and contamination-based obsessive-compulsive symptoms.

Authors:  Christal L Badour; Stephanie Bown; Thomas G Adams; Liviu Bunaciu; Matthew T Feldner
Journal:  J Anxiety Disord       Date:  2012-03-14

5.  Repetitive behaviours in patients with Gilles de la Tourette syndrome: tics, compulsions, or both?

Authors:  Yulia Worbe; Luc Mallet; Jean-Louis Golmard; Cécile Béhar; Franck Durif; Isabelle Jalenques; Philippe Damier; Pascal Derkinderen; Pierre Pollak; Mathieu Anheim; Emannuel Broussolle; Jing Xie; Valérie Mesnage; Karl Mondon; François Viallet; Pierre Jedynak; Mouna Ben Djebara; Michael Schüpbach; Antoine Pelissolo; Marie Vidailhet; Yves Agid; Jean-Luc Houeto; Andreas Hartmann
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

6.  A study of diagnostic accuracy of the Florida Obsessive-Compulsive Inventory--Thai Version (FOCI-T).

Authors:  Ratana Saipanish; Thanita Hiranyatheb; Sudawan Jullagate; Manote Lotrakul
Journal:  BMC Psychiatry       Date:  2015-10-14       Impact factor: 3.630

7.  Sequential allocation to balance prognostic factors in a psychiatric clinical trial.

Authors:  Victor Fossaluza; Juliana Belo Diniz; Basilio de Bragança Pereira; Eurípedes Constantino Miguel; Carlos Alberto de Bragança Pereira
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

8.  Management of obsessive-compulsive disorder with fluvoxamine extended release.

Authors:  Lídia Ordacgi; Mauro V Mendlowicz; Leonardo F Fontenelle
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

Review 9.  Nutritional therapies for mental disorders.

Authors:  Shaheen E Lakhan; Karen F Vieira
Journal:  Nutr J       Date:  2008-01-21       Impact factor: 3.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.